U-CaVIT Versus Standard of Care for Prevention of Atonic Postpartum Hemorrhage After Cesarean Section in High-risk Women.
NCT ID: NCT07019623
Last Updated: 2025-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
70 participants
INTERVENTIONAL
2025-05-09
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The U-CaVIT method has been implemented at the Department of Obstetrics at university hospital of Zurich (USZ) due to temporary supply issues with the Bakri® Balloon Catheter. The Rüsch® Balloon Catheter is used in case of uterine atony when standard first-line uterotonic treatments have failed or in some cases as add-on therapy in non-atonic PPH. In the meantime, the use of U-CaVIT has become standard practice at the USZ for the treatment of atonic PPH, appearing to be user-friendly, clinically effective according to treating physicians, well tolerated by the treated women and cost-saving compared to the previously used Bakri® Balloon.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnancy With High Risk for PPH
NCT04089176
Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections
NCT03651882
Does the Rapid Intravenous Administration of Oxytocin After Delivery of the Baby Decrease the Bleeding During Cesarean Section in Women at Risk of Bleeding During Cesarean Section?
NCT00257803
Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain
NCT02642263
Post-Cesarean Wound Drainage is Not Necessary in Women at Increased Risk of Hemorrhage
NCT00779727
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
According to the WHO, PPH is defined as blood loss of 500 mL or more within 24 hours after delivery, and it causes about 30% of maternal deaths worldwide. The internationally observed trend towards increased PPH-related morbidity and mortality is disturbing and demands new strategies in the prevention and treatment of PPH.
The underlying causes of PPH are uterine atony (Tonus), trauma (Trauma), placental disorders (Tissue), and coagulopathy/hemorrhagic diathesis (Thrombin) as well as disorder of the coagulation system which itself aggravates bleeding. Among these, uterine atony, which prevents mechanical hemostasis, is thought to be responsible for 60-80% of PPH cases and remains one of the most frequent causes of postpartum hysterectomy.
Therapy of uterine atony is based on the use of uterotonic drugs, nonsurgical approaches (e.g., uterine massage, intrauterine tamponade with an intrauterine balloon, vacuum device, or packing) as well as surgical therapies (e.g., repair of a deep laceration or tear in the uterus, cervix, or vagina; uterine artery ligation; curettage; uterine compression sutures; hysterectomy). A reasoned and sequential treatment approach is based on a multistage strategy that starts from less invasive interventions proceeding to more invasive methods. The strategic goal is to prevent severe PPH by implementing a minimally invasive, effective and low-cost method at an early stage of PPH or even before PPH might occur in high-risk patients, who inherently have an increased bleeding risk following a cesarean section. This would result in an enormous benefit to the patient in terms of morbidity and mortality as well as a consistent and judicious approach in the use of resources.
In an atonic uterus, vessels are not constricted and hemorrhage ensues, prompting first-line therapy. When medical management alone is deemed unsuccessful, balloon tamponade is currently the next treatment option added to control uterine atony. A balloon is placed within the uterus and inflated with sterile saline solution to put sustained pressure on the uterus from the inside. The Bakri® Balloon (Cook Medical) is currently the most commonly described intrauterine tamponade balloon device in the literature. By applying external pressure to the uterine walls for 12-24 hours, the uterus may then involute and regain normal tone. Although tamponade has been demonstrated to be effective in controlling hemorrhage in 87% (95% CI 84-90%) of atony-related cases, the mechanism of action of using outward pressure to control bleeding from uterine atony is counterintuitive if the ultimate goal is uterine contraction.
Recently, intrauterine vacuum devices have been introduced, offering a new mechanism for achieving hemorrhage control by applying low-level intrauterine vacuum to facilitate the physiological forces of uterine contractions, constrict myometrial blood vessels, and achieve hemostasis. Unlike the Bakri® Balloon, this device is not inflated but induces negative pressure in the uterine cavity, an approach called vacuum-induced tamponade. Purwosunu et al. conducted a proof-of-concept investigation involving 10 women. The rationale for creating negative pressure is that the vacuum extracts intrauterine blood and, by reducing uterine volume, promotes physiological uterine contraction, constricts the spiral arteries, and thus controls uterine atony.
In 2017, the Department of Obstetrics at USZ introduced another vacuum tamponade system, using a modified Bakri® balloon system (off-label use) to achieve intrauterine vacuum. According to the SOP at USZ, the balloon is filled with sterile fluid (60-80 mL) and connected with a vacuum-device applying a low-level intrauterine vacuum (-60 to a maximum of -70 kPa).
All women with primary PPH at the USZ, who were treated with vacuum-induced tamponade (i.e., with the modified Bakri® Balloon System) between March 2017 and June 2020, were analyzed. It was concluded that the vacuum-induced tamponade is an easy-to-use technique, and second, that vacuum-induced tamponade is associated with the highest success rate (defined as no need for additional interventional treatment such as surgical intervention or embolization of the pelvic arteries) in women with uterine atony.
Due to temporary worldwide supply difficulties of the Bakri® Balloon, the Rüsch® Balloon Catheter was introduced at USZ in June 2023 (also off-label use). As it is an urological catheter, this new approach was called U-CaVIT (Uro-Catheter Vacuum Induced Tamponade). It quickly gained favor among treating physicians due to its ease of use and apparent excellent performance. The use of the Rüsch® Balloon Catheter instead of the \>20 times more expensive Bakri® Balloon, has become standard practice at the Department of Obstetrics for the treatment of atonic PPH: When indicated (i.e. when the standard uterotonic PPH treatment consisting of the administration of oxytocin or carbetocin followed by prostaglandins has failed, or when bleeding continues despite removal of the placenta or retained placental tissue), the Rüsch® Balloon Catheter is used according to the USZ internal SOP "Vakuuminduzierte Tamponade".
Given the substantial burden of PPH and its high mortality rates, especially in low-income countries, the development of low-cost yet highly effective methods such as U-CaVIT with the Rüsch® Balloon Catheter is crucial for improving maternal outcomes globally, extending beyond developed nations. To address this need, the investigators conduct this clinical trial to systematically evaluate the U-CaVIT approach (using the Rüsch® Balloon Catheter) as a prophylactic measure in high-risk post-cesarean section patients. Furthermore, this pilot clinical investigation will provide reliable data and pave the way for the competitive funding of a large-scale, national, multi-center pivotal study to evaluate the effect of this method in women at risk of PPH. The impact might be significant both in terms of patient outcomes and the reduction of PPH-related costs during hospitalization.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
U-CaVIT
Prophylactic treatment with Rüsch® Balloon Catheter Ch. 24
Rüsch® Balloon Catheter Ch. 24
After cesarean delivery, patients in the intervention group receive the following intervention: The Rüsch® Balloon Catheter Ch. 24 will be inserted directly into the uterus before uterotomy closure.
After insertion of the catheter, the catheter balloon is filled with 60 - 80 ml of 0.9% saline solution and connected to the vacuum device whereby an intrauterine vacuum of -60 to a maximum of -70 kPa is applied once the uterotomy is closed. Once the catheter has been positioned, it is left in place for one hour as a prophylactic measure while a vacuum is applied.
The device will be removed by draining the liquid in the balloon, after 1 hour of vacuum-induced tamponade. The final decision for removal of the catheter in this study is made by the senior physician responsible for the woman.
Ultrasonography
The position of the balloon catheter as well as the condition of the uterine cavity are assessed immediately postoperatively using ultrasonography.
Control
Women in the control group will be treated according to the standard of care procedure.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rüsch® Balloon Catheter Ch. 24
After cesarean delivery, patients in the intervention group receive the following intervention: The Rüsch® Balloon Catheter Ch. 24 will be inserted directly into the uterus before uterotomy closure.
After insertion of the catheter, the catheter balloon is filled with 60 - 80 ml of 0.9% saline solution and connected to the vacuum device whereby an intrauterine vacuum of -60 to a maximum of -70 kPa is applied once the uterotomy is closed. Once the catheter has been positioned, it is left in place for one hour as a prophylactic measure while a vacuum is applied.
The device will be removed by draining the liquid in the balloon, after 1 hour of vacuum-induced tamponade. The final decision for removal of the catheter in this study is made by the senior physician responsible for the woman.
Ultrasonography
The position of the balloon catheter as well as the condition of the uterine cavity are assessed immediately postoperatively using ultrasonography.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Maternal age ≥18 years
* Gestational age ≥34+0 weeks of pregnancy at day of delivery
* Vital pregnancy
* Delivery mode: planned cesarean delivery
* High-risk patient for PPH specified by the presence of at least one of the following characteristics: Previous PPH, obesity (BMI ≥30 kg/m2), high parity (patient who has had ≥4 previous births (live or stillborn) at ≥20 weeks of gestation), very advanced maternal age ≥45 years, multiple gestation, polyhydramnios (defined as amniotic fluid index \> 25 cm or deepest amniotic fluid pocket \> 8 cm) at admission to delivery, suspected fetal macrosomia (estimated fetal weight ≥ 4500g)
Exclusion Criteria
* Participation in another interventional study
* Emergency cesarean section (incl. patients undergoing cesarean after failed vaginal delivery)
* Women with regular and painful contractions and women who do not have time for sufficient consideration
* Clinical situations in which vacuum-induced uterine tamponade is unlikely to be effective or is contraindicated: Uterine or vaginal anomalies (genital tract congenital anomalies), cesarean section due to placenta previa or suspected placenta accreta spectrum, suspected uterine rupture, injuries of the cervix or vagina, submucous or intramural uterine fibroids which are buldging into the uterine cavity, deep endometriosis
* Planned atony-prophylaxis with oxytocin due to contraindication for carbetocin
* Previous MMC-repair (myelomeningocele-repair)
* Clinical diagnosis of chorioamnionitis, sepsis
* Allergy to any component of the device
* Known and proven diagnosis of bleeding disorder or thrombophilia
* Known thrombocytopenia during second half of pregnancy with thrombocytes \< 100 G/L
* Known anemia during second half of pregnancy with Hb\<80 g/L
* Cervix deemed too stiff and/or stenotic for U-CaVIT application, judged by the surgeon during the intra-operative assessment.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Christian Haslinger
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christian Haslinger
Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Prof. Dr. med. Christian Haslinger, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Zürich, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Goffman D, Rood KM, Bianco A, Biggio JR, Dietz P, Drake K, Heilman E, Hopkins M, De Four Jones M, Katz T, Martin C, Prasad M, Smid MC, Wine KD, Ryan R, Yong C, Carney PI, Simhan HN. Real-World Utilization of an Intrauterine, Vacuum-Induced, Hemorrhage-Control Device. Obstet Gynecol. 2023 Nov 1;142(5):1006-1016. doi: 10.1097/AOG.0000000000005366. Epub 2023 Sep 13.
D'Alton ME, Rood KM, Smid MC, Simhan HN, Skupski DW, Subramaniam A, Gibson KS, Rosen T, Clark SM, Dudley D, Iqbal SN, Paglia MJ, Duzyj CM, Chien EK, Gibbins KJ, Wine KD, Bentum NAA, Kominiarek MA, Tuuli MG, Goffman D. Intrauterine Vacuum-Induced Hemorrhage-Control Device for Rapid Treatment of Postpartum Hemorrhage. Obstet Gynecol. 2020 Nov;136(5):882-891. doi: 10.1097/AOG.0000000000004138.
Purwosunu Y, Sarkoen W, Arulkumaran S, Segnitz J. Control of Postpartum Hemorrhage Using Vacuum-Induced Uterine Tamponade. Obstet Gynecol. 2016 Jul;128(1):33-36. doi: 10.1097/AOG.0000000000001473.
Haslinger C, Weber K, Zimmermann R. Vacuum-Induced Tamponade for Treatment of Postpartum Hemorrhage. Obstet Gynecol. 2021 Sep 1;138(3):361-365. doi: 10.1097/AOG.0000000000004510.
Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, Gulmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BASEC No. 2024-D0099
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.